Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adriaan A Voors

Showing results (1-10 of 857) with videos related to

Pageof 86
Sort By:
JACC. Heart Failure|February 12, 2018
Sense and Sensibility of the Use of NT-proBNP for Eligibility in Clinical TrialsAdriaan A Voors
Expert Opinion on Investigational Drugs|June 28, 2007
Vascular benefits of angiotensin receptor blockersAdriaan A Voors
JACC. Heart Failure|March 16, 2020
Should Enrichment With Natriuretic Peptide Levels Be Mandatory in Global Clinical Trials?Adriaan A Voors
Journal of Cardiac Failure|September 4, 2023
Novel Recommendations for the Treatment of Patients With Heart Failure: 2023 Focused Update of the 2021 ESC Heart Failure GuidelinesAdriaan A Voors
Nature Reviews. Cardiology|January 9, 2013
Trial data resolve gaps in evidence-based treatmentAdriaan A Voors
Nederlands Tijdschrift Voor Geneeskunde|September 30, 2009
[The value of physical training in patients with heart failure]Adriaan A Voors
Nederlands Tijdschrift Voor Geneeskunde|July 10, 2014
[Spironolactone not effective in diastolic heart failure]Adriaan A Voors
European Heart Journal|June 27, 2022
Heart failure medication: moving from evidence generation to implementationJasper Tromp, Adriaan A Voors
Heart Failure Reviews|February 28, 2012
The puzzle of kidney dysfunction in heart failure: an introductionMarco Metra, Adriaan A Voors
JACC. Heart Failure|July 17, 2017
The Fastest Way to the Failing Heart Is Through the KidneysKevin Damman, Adriaan A Voors
Pageof 86

Showing results (1-10 of 857) with videos related to

Sort By:
Pageof 86
JACC. Heart Failure|February 12, 2018
Sense and Sensibility of the Use of NT-proBNP for Eligibility in Clinical TrialsAdriaan A Voors
Expert Opinion on Investigational Drugs|June 28, 2007
Vascular benefits of angiotensin receptor blockersAdriaan A Voors
JACC. Heart Failure|March 16, 2020
Should Enrichment With Natriuretic Peptide Levels Be Mandatory in Global Clinical Trials?Adriaan A Voors
Journal of Cardiac Failure|September 4, 2023
Novel Recommendations for the Treatment of Patients With Heart Failure: 2023 Focused Update of the 2021 ESC Heart Failure GuidelinesAdriaan A Voors
Nature Reviews. Cardiology|January 9, 2013
Trial data resolve gaps in evidence-based treatmentAdriaan A Voors
Nederlands Tijdschrift Voor Geneeskunde|September 30, 2009
[The value of physical training in patients with heart failure]Adriaan A Voors
Nederlands Tijdschrift Voor Geneeskunde|July 10, 2014
[Spironolactone not effective in diastolic heart failure]Adriaan A Voors
European Heart Journal|June 27, 2022
Heart failure medication: moving from evidence generation to implementationJasper Tromp, Adriaan A Voors
Heart Failure Reviews|February 28, 2012
The puzzle of kidney dysfunction in heart failure: an introductionMarco Metra, Adriaan A Voors
JACC. Heart Failure|July 17, 2017
The Fastest Way to the Failing Heart Is Through the KidneysKevin Damman, Adriaan A Voors
Pageof 86